GlassScriptPhysician profile
Deanna D Campbell
NPI 1093918096
$1,142.32
in general payments reported to CMS, 2019-2025
19 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $254 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $119.73 | 2022-2025 | |
| Vifor Pharma, INC. | $112.52 | 2021-2025 | Veltassa |
| Shield Therapeutics INC | $106.83 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.16 | 2021-2025 | |
| Amgen INC. | $94.81 | 2021-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $94.45 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $82.12 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $66.54 | 2025 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $52.14 | 2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $50.18 | 2025 | Acthar, Terlivaz |
| Scpharmaceuticals INC. | $42.57 | 2025 | |
| Novartis Pharmaceuticals Corporation | $38.71 | 2025 | |
| Akebia Therapeutics INC | $37.82 | 2021-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.80 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $31.08 | 2025 | Arexvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.45 | 2025 | Injectafer |
| Novo Nordisk INC | $20.93 | 2025 | Ozempic |
| Nxstage Medical, INC. | $18.45 | 2025 | Nxstage System One |
| Horizon Therapeutics Plc | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.